Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis
Journal of Drugs in Dermatology · 2024
DOI: 10.36849/jdd.8217 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Drugs in Dermatology, 2024. Verfasst von Jayme Heim und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Severity of Illness Index. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Heim, J., Vasquez, J. G., Bhutani, T., Koo, J., Mathew, J., Gogineni, R., Ferro, T., & Bhatia, N. (2024). Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.8217
Vancouver
Heim J, Vasquez JG, Bhutani T, Koo J, Mathew J, Gogineni R, et al. Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.8217
BibTeX
@article{Heim2024,
author = {Heim, Jayme and Vasquez, J Gabriel and Bhutani, Tina and Koo, John and Mathew, Jacob and Gogineni, Ranga and Ferro, Thomas and Bhatia, Neal},
title = {Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis},
journal = {Journal of Drugs in Dermatology},
year = {2024},
doi = {10.36849/jdd.8217}
}
EUVIMED